Literature DB >> 30610955

HMGB1/TLR4 promotes hypoxic pulmonary hypertension via suppressing BMPR2 signaling.

Jin Wang1, Xiao-Ting Tian2, Zhouyf Peng3, Wen-Qun Li4, Yuan-Yuan Cao2, Ying Li5, Xiao-Hui Li6.   

Abstract

High mobility group box 1 (HMGB1), a critical nonclassical inflammatory cytokine, has been found up-regulated in patients with idiopathic pulmonary arterial hypertension (IPAH), but its role in vascular remodeling of pulmonary hypertension (PH) is still unknown. In present study, we demonstrated that the plasma level of inflammatory cytokine including HMGB1, interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α) were elevated in hypoxia-induced pulmonary hypertension rats model. Moreover, expressions of HMGB1 and Toll like receptor-4 (TLR4) in pulmonary arteries were obviously up-regulated accompanied with down-regulation of bone morphogenetic protein receptor 2 (BMPR2) signaling, characterized by decline of phosphorylated Smad1/5/8 (p-Smsd1/5/8) and inhibitor of differention 1 (Id1) expression. In cultured primary pulmonary arterial smooth muscle cells (PASMCs), we found that HMGB1 incubation significantly promoted proliferation and migration of PASMCs, down-regulated p-Smsd1/5/8 and Id1 expression, which can be abrogated by HMGB1 inhibitors saquinavir, glycyrrhizn and TLR4 inhibitors TAK-242. Furthermore, saquinavir, glycyrrhizn and TAK-242 treatment significantly attenuated the development of PH in rats by recovering homodynamic parameters, pulmonary vascular remodeling and BMPR2 signaling pathway. In summary, our results suggest that HMGB1/TLR4 signaling promotes hypoxia-induced pulmonary hypertension via suppressing BMPR2 signaling.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMPR2; HMGB1; Inflammation; Pulmonary hypertension; TLR4

Mesh:

Substances:

Year:  2019        PMID: 30610955     DOI: 10.1016/j.vph.2018.12.006

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  10 in total

Review 1.  Pulmonary hypertension: Pathophysiology beyond the lung.

Authors:  Aline C Oliveira; Elaine M Richards; Mohan K Raizada
Journal:  Pharmacol Res       Date:  2019-11-13       Impact factor: 7.658

Review 2.  The Potential Application and Promising Role of Targeted Therapy in Pulmonary Arterial Hypertension.

Authors:  Meng-Chien Willie Hsieh; Wei-Ting Wang; Jwu-Lai Yeh; Chuang-Yu Lin; Yur-Ren Kuo; Su-Shin Lee; Ming-Feng Hou; Yi-Chia Wu
Journal:  Biomedicines       Date:  2022-06-15

3.  Necrosis-Released HMGB1 (High Mobility Group Box 1) in the Progressive Pulmonary Arterial Hypertension Associated With Male Sex.

Authors:  Marina Zemskova; Nolan McClain; Maki Niihori; Mathews V Varghese; Joel James; Ruslan Rafikov; Olga Rafikova
Journal:  Hypertension       Date:  2020-10-05       Impact factor: 10.190

Review 4.  RNA Signaling in Pulmonary Arterial Hypertension-A Double-Stranded Sword.

Authors:  Helena A Turton; A A Roger Thompson; Laszlo Farkas
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

5.  Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb.

Authors:  Mohamed Ahmed; Nahla Zaghloul; Prisca Zimmerman; Nancy G Casanova; Xiaoguang Sun; Jin H Song; Vivian Reyes Hernon; Saad Sammani; Franz Rischard; Olga Rafikova; Ruslan Rafikov; Ayako Makino; Carrie L Kempf; Sara M Camp; Jian Wang; Ankit A Desai; Yves Lussier; Jason X-J Yuan; Joe G N Garcia
Journal:  Pulm Circ       Date:  2021-11-12       Impact factor: 2.886

Review 6.  Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Jaylen Hudson; Laszlo Farkas
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

Review 7.  Cellular mechanosignaling in pulmonary arterial hypertension.

Authors:  Ariel Wang; Daniela Valdez-Jasso
Journal:  Biophys Rev       Date:  2021-09-02

Review 8.  High Mobility Group Box 1: Biological Functions and Relevance in Oxidative Stress Related Chronic Diseases.

Authors:  Simona Taverna; Alessandro Tonacci; Maria Ferraro; Giuseppe Cammarata; Giuseppina Cuttitta; Salvatore Bucchieri; Elisabetta Pace; Sebastiano Gangemi
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

9.  Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway.

Authors:  Na Liang; Wenfeng Zhang; Hongjiang Wang; Wei Shi; Li Wang; Lijuan Ma
Journal:  Drug Des Devel Ther       Date:  2020-08-24       Impact factor: 4.162

Review 10.  When Innate Immunity Meets Angiogenesis-The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension.

Authors:  Aneel Bhagwani; A A Roger Thompson; Laszlo Farkas
Journal:  Front Med (Lausanne)       Date:  2020-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.